Plat, imo, missed one; 8) Pump in process.
Regardless of unfolding events, IF CR on the horizon, pump whether with substance or not absolutely needed to be able to raise at highest possible sp, for obvious reasons, again IF CR on the horizon.
I recollect when sp was pushed into the low forties, did think at the time a turn around was in the making, then a CR followed, harbinger of the future!
Past history of this company, till this very date, has shown RI NOT to take anything for granted any longer, WP/Admedus spiel not that long ago was the final nail, imo, in damaging what was left of any credibility the company owned.
Future of company; needs to continue to trade as a public company without the continual reliance on CRs, SIO and SB to take full control on the running of this company after the announcement ‘WP will be moving on, has done so much for this company bla bla’ in 2020.
Clout and connections of both entities should finally see some traction in gaining meaningful inroads on incumbent giants.
Above is best case scenario, worst case ......?
- Forums
- ASX - By Stock
- AVR
- News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval
News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval, page-516
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$9.91 |
Change
-0.090(0.90%) |
Mkt cap ! $209.4M |
Open | High | Low | Value | Volume |
$10.00 | $10.00 | $9.65 | $70.76K | 7.202K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 300 | $9.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$9.91 | 475 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 300 | 9.800 |
1 | 200 | 9.600 |
1 | 2 | 9.540 |
1 | 330 | 9.510 |
2 | 1185 | 9.500 |
Price($) | Vol. | No. |
---|---|---|
9.910 | 475 | 2 |
9.990 | 99 | 1 |
10.000 | 250 | 1 |
10.500 | 10005 | 2 |
11.000 | 5000 | 1 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online